Science To Consumers Stock Performance
| BEUT Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Science To are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Science to Consumers has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Science To is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Science |
Science To Relative Risk vs. Return Landscape
If you would invest 0.01 in Science to Consumers on September 27, 2025 and sell it today you would earn a total of 0.00 from holding Science to Consumers or generate 0.0% return on investment over 90 days. Science to Consumers is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Science, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Science To Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Science To's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Science to Consumers, and traders can use it to determine the average amount a Science To's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BEUT |
Based on monthly moving average Science To is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Science To by adding Science To to a well-diversified portfolio.
Science To Fundamentals Growth
Science Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Science To, and Science To fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Science Pink Sheet performance.
| Return On Asset | -4.4 | |||
| Current Valuation | 1.18 M | |||
| Shares Outstanding | 31.92 M | |||
| Price To Earning | (17.50) X | |||
| Price To Book | 955.49 X | |||
| EBITDA | (51.17 K) | |||
| Cash And Equivalents | 1.44 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (47.69 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 11.73 K | |||
| Retained Earnings | (162 K) | |||
| Current Asset | 2 K | |||
| Current Liabilities | 68 K | |||
About Science To Performance
Assessing Science To's fundamental ratios provides investors with valuable insights into Science To's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Science To is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Science to Consumers, Inc., a development stage company, focuses on marketing and selling formulated anti-aging cream products under the DermaLastyl name and distributing Argan oil products. Science to Consumers, Inc. was founded in 2013 and is based in Guangzhou, China. Science To is traded on OTC Exchange in the United States.Things to note about Science to Consumers performance evaluation
Checking the ongoing alerts about Science To for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Science to Consumers help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Science to Consumers generated a negative expected return over the last 90 days | |
| Science to Consumers has some characteristics of a very speculative penny stock | |
| Science to Consumers has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Science To until it has trouble settling it off, either with new capital or with free cash flow. So, Science To's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Science to Consumers sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Science to invest in growth at high rates of return. When we think about Science To's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (58.7 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Science to Consumers currently holds about 1.44 K in cash with (47.69 K) of positive cash flow from operations. | |
| Roughly 66.0% of the company shares are held by company insiders |
- Analyzing Science To's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Science To's stock is overvalued or undervalued compared to its peers.
- Examining Science To's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Science To's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Science To's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Science To's pink sheet. These opinions can provide insight into Science To's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Science Pink Sheet Analysis
When running Science To's price analysis, check to measure Science To's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Science To is operating at the current time. Most of Science To's value examination focuses on studying past and present price action to predict the probability of Science To's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Science To's price. Additionally, you may evaluate how the addition of Science To to your portfolios can decrease your overall portfolio volatility.